BIOGENED S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.6 PLN | -0.92% |
|
-1.82% | +20.00% |
| 05-15 | Biogened S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 02-14 | Biogened S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 79.62M 19.7M 27.01M | Sales 2023 | 95.56M 23.65M 32.42M | Capitalization | 44.21M 10.94M 15M |
|---|---|---|---|---|---|
| Net income 2022 | 3M 742K 1.02M | Net income 2023 | 5M 1.24M 1.7M | EV / Sales 2022 | 0.64 x |
| Net Debt 2022 | 19.52M 4.83M 6.62M | Net Debt 2023 | 14.94M 3.7M 5.07M | EV / Sales 2023 | 0.62 x |
| P/E ratio 2022 |
9.23
x | P/E ratio 2023 |
8.67
x | Employees | 204 |
| Yield 2022 |
3.15% | Yield 2023 |
2.78% | Free-Float | 5.89% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.92% | ||
| 1 week | -1.82% | ||
| Current month | +20.00% | ||
| 1 month | +5.88% | ||
| 3 months | -30.32% | ||
| 6 months | +20.00% | ||
| Current year | +20.00% |
1 week
19.00
22.00
1 month
16.7022.20
Current year
16.2032.60
1 year
13.6032.60
3 years
6.2032.60
5 years
6.2032.60
10 years
5.0032.60
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 11-11-02 | |
| Director of Finance/CFO | 62 | - | |
| Chairman | 82 | 06-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 11-11-02 | |
| Chairman | 82 | 06-12-31 | |
| Director/Board Member | 49 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-21 | 21.6 | -0.92% | 35 |
| 24-06-19 | 21.8 | 0.00% | 22 |
| 24-06-18 | 21.8 | -0.91% | 77 |
| 24-06-17 | 22 | 0.00% | 50 |
| 24-06-14 | 22 | +3.77% | 108 |
End-of-day quote Warsaw S.E., June 20, 2024
More quotes
Biogened SA is a Poland-based company active in the healthcare sector. The Company is engaged in production and distribution of generic pharmaceuticals in psychiatry, neurology and oncology, as well as development, production and distribution of dermocosmetics and diet supplements. The Companyâs product portfolio includes: Polmantis and SST Salvia Stimulating Tablets (pharmaceuticals), Dermedic, Ellexir, Herba Botanic and Novoscabin (dermocosmetics), and Fibers, Prolady, Futimal and Dermedic Caps (diet supplemenst). As of March 31, 2012, Life Science Technologies NV held an 80.92% stake in the capital.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +20.00% | 13.1M | |
| +16.50% | 42.12B | |
| +20.78% | 21.72B | |
| +21.14% | 15.75B | |
| +23.69% | 14.89B | |
| +57.44% | 13.06B | |
| -0.05% | 6.79B | |
| -14.94% | 6.3B | |
| +20.03% | 6.05B | |
| -8.87% | 5.73B |
- Stock Market
- Equities
- BGD Stock
